Meaxin (Imatinib)

Imatinib acts on malignancies driven by BCR‑ABL, c‑KIT or PDGFR tyrosine kinases, offering disease control in several cancer types.

• Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven proliferation to achieve hematologic and cytogenetic remission.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): inhibits leukemic blast growth and improves remission rates.
• Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling to reduce tumor size and delay progression.
• Other BCR‑ABL positive malignancies: provides targeted inhibition to control disease activity.

• Imatinib selectively binds to the ATP‑binding site of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream substrates. This blockade halts proliferative signaling pathways, induces apoptosis in malignant cells, and reduces tumor angiogenesis, thereby limiting disease progression in cancers dependent on these kinases.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Edema: peripheral swelling, often in the ankles.
• Muscle cramps: intermittent skeletal muscle discomfort.
• Fatigue: generalized tiredness affecting daily activities.
• Diarrhea: loose stools, sometimes requiring fluid replacement.
• Rash: mild skin erythema or pruritus.

Serious or Rare Side Effects

• Neutropenia: significant drop in white blood cells, increasing infection risk.
• Hepatotoxicity: elevated liver enzymes or jaundice indicating liver injury.
• Cardiac failure: signs of reduced cardiac output, such as dyspnea.
• Severe hemorrhage: unexpected bleeding events, especially with concurrent anticoagulants.
• Interstitial lung disease: progressive dyspnea and cough with radiographic infiltrates.

Patients should be monitored closely for safety concerns throughout therapy.

• Monitor blood counts: perform regular CBC to detect cytopenias.
• Assess liver function: schedule periodic LFTs to identify hepatotoxicity.
• Check cardiac status: evaluate for signs of heart failure before and during treatment.
• Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs.
• Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Imatinib may interact with several concomitant medicines, requiring dose adjustments or monitoring.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole): can raise imatinib plasma levels and increase toxicity.
• CYP3A4 inducers (e.g., rifampin): may lower drug exposure, reducing efficacy.
• Warfarin: concurrent use can enhance anticoagulant effect and raise bleeding risk.

Moderate Interactions (Monitor Closely)

• Antacids containing aluminum or magnesium: may reduce oral absorption of imatinib.
• Live vaccines: immunogenic response may be diminished.
• Diuretics (e.g., furosemide): can exacerbate electrolyte disturbances when combined with imatinib.